Related Experiment Video
Updated: Dec 13, 2025
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Perspective on human pluripotent stem cell-derived cardiomyocytes in heart disease modeling and repair
Qiang Li1,2, Jia Wang3,4, Qiang Wu1,2
1CAS Key Laboratory of Tissue Microenvironment and Tumor, Laboratory of Molecular Cardiology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences (CAS), Shanghai, People's Republic of China.
Insights
Human pluripotent stem cells (hPSCs) offer promise for treating heart disease (HD) by generating patient-specific cardiomyocytes. However, obstacles remain in their clinical application and understanding HD mechanisms.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Regenerative Medicine
Background:
- Heart diseases (HDs) are a primary global cause of death.
- Current treatments for HDs cannot regenerate lost heart muscle.
- Understanding genotype-phenotype correlations in HDs is limited.
Purpose of the Study:
- To review advances in using human pluripotent stem cell (hPSC)-derived cardiomyocytes for cardiac therapy.
- To discuss the application of hPSC-derived cardiomyocytes in understanding HD mechanisms.
- To identify challenges and potential solutions for hPSC-based cardiac applications.
Main Methods:
- Review of recent scientific literature on hPSC biology and cardiac applications.
- Analysis of progress in generating cardiomyocytes from hPSCs.
- Discussion of preclinical and clinical studies utilizing hPSC-derived cardiomyocytes.
Main Results:
- hPSC technology enables patient-specific cardiomyocyte generation.
- hPSC-derived cardiomyocytes show potential in preclinical cardiac repair and disease modeling.
- Significant obstacles hinder the widespread clinical use of hPSC-based therapies.
Conclusions:
- hPSC-derived cardiomyocytes represent a promising avenue for cardiac regenerative medicine.
- Further research is needed to overcome current limitations in hPSC applications for heart disease.
- Addressing challenges will advance hPSC-based strategies for HD treatment and mechanistic studies.
Abstract:
Heart diseases (HDs) are the leading cause of morbidity and mortality worldwide. Despite remarkable clinical progress made, current therapies cannot restore the lost myocardium, and the correlation of genotype to phenotype of many HDs is poorly modeled. In the past two decades, with the rapid developments of human pluripotent stem cell (hPSC) biology and technology that allow the efficient preparation of cardiomyocytes from individual patients, tremendous efforts have been made for using hPSC-derived cardiomyocytes in preclinical and clinical cardiac therapy as well as in dissection of HD mechanisms to develop new methods for disease prediction and treatment. However, their applications have been hampered by several obstacles. Here, we discuss recent advances, remaining challenges, and the potential solutions to advance this field.
More Related Videos
09:23Generation, High-Throughput Screening, and Biobanking of Human-Induced Pluripotent Stem Cell-Derived Cardiac Spheroids
Published on: March 10, 2023
09:35Preclinical Cardiac Electrophysiology Assessment by Dual Voltage and Calcium Optical Mapping of Human Organotypic Cardiac Slices
Published on: June 16, 2020
